Last reviewed · How we verify

vaccinate with DT

Zhejiang Provincial Center for Disease Control and Prevention · FDA-approved active Biologic

DT vaccine stimulates the immune system to produce antibodies against diphtheria and tetanus toxins, providing protective immunity against these bacterial diseases.

DT vaccine stimulates the immune system to produce antibodies against diphtheria and tetanus toxins, providing protective immunity against these bacterial diseases. Used for Prevention of diphtheria, Prevention of tetanus.

At a glance

Generic namevaccinate with DT
SponsorZhejiang Provincial Center for Disease Control and Prevention
Drug classVaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease Prevention
PhaseFDA-approved

Mechanism of action

The DT vaccine contains inactivated diphtheria and tetanus toxoids (toxins rendered harmless), which trigger the adaptive immune response to generate antibodies and memory cells. Upon exposure to wild-type Corynebacterium diphtheriae or Clostridium tetani, these pre-formed antibodies neutralize the bacterial toxins before they can cause systemic disease. This is a toxoid-based immunization strategy that has been standard public health practice for decades.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: